These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Ultra-low-dose, time-resolved contrast-enhanced magnetic resonance angiography of the carotid arteries at 3.0 tesla.
    Author: Lohan DG, Tomasian A, Saleh RS, Singhal A, Krishnam MS, Finn JP.
    Journal: Invest Radiol; 2009 Apr; 44(4):207-17. PubMed ID: 19300100.
    Abstract:
    PURPOSE: To determine whether time-resolved magnetic resonance angiography (TR-MRA) with ultra-low-dose gadolinium chelate (1.5-3.0 mL) can reliably detect or rule out hemodynamically significant disease in the carotid-vertebral artery territory. MATERIALS AND METHODS: Hundred consecutive patients (62 women, 38 men, mean age = 56.6 years) underwent both TR-MRA and standard high-resolution contrast-enhanced magnetic resonance angiography (CE-MRA), having been randomized to 1 of 2 groups; group A receiving a contrast dose of 1.5 mL for TR-MRA and group B receiving 3.0 mL. For scoring purposes the arterial system was divided into 21 segments. All TR-MRA and CE-MRA studies were blindly assessed by 2 radiologists for overall image quality, segmental arterial visualization, grading of arterial stenosis/occlusion, and incidence and severity of artifact. TR-MRA findings were directly compared with those of the corresponding CE-MRA examinations. RESULTS: Group A TR-MRA studies were of significantly inferior overall image quality compared with those of the corresponding CE-MRA examinations (P = 0.01 for both observers). In group B, overall image quality was similar for TR-MRA and single-phase CE-MRA examinations. On a segmental basis, a higher number of "insufficient quality" segments were identified in group A TR-MRA studies than in group B. A similar reduction in the incidence of artifacts was observed for group B relative to group A TR-MRA studies. Both groups A and B TR-MRA studies were of high specificity, negative predictive values, and accuracy (>97%). CONCLUSION: Ultra-low dose TR-MRA may be performed with 3 mL of gadolinium chelate with preservation of overall image quality and arterial segmental visualization relative to single phase CE-MRA, whereas a 1.5 mL contrast dose is associated with more suboptimal studies. Nonetheless, even at doses as low as 1.5 mL, TR-MRA can exclude arterial stenosis or occlusion.
    [Abstract] [Full Text] [Related] [New Search]